Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is
1. to determine the recommended dose of everolimus for a subsequent Phase II trial
2. to determine the efficacy of everolimus plus DHAP